Silymarin: not just another antioxidant

References

[1] Abenavoli L, Capasso R, Milic N, Capasso F. Milk thistle in liver diseases: Past, present, future. Phytother Res 2010;24:1423–32.10.1002/ptr.3207Search in Google Scholar PubMed

[2] Greenlee H, Abascal K, Yarnell E, Ladas E. Clinical application of Silybum marianum in oncology. Integr Cancer Ther 2007;6:158–65.10.1177/1534735407301727Search in Google Scholar PubMed

[3] Federico A, Dallio M, Loguercio C. Silymarin/Silybin and chronic liver disease: a marriage of many years. Molecules 2017;22:191.10.3390/molecules22020191Search in Google Scholar PubMed PubMed Central

[4] Tajmohammadi A, Razavi BM, Hosseinzadeh H. Silybum marianum (milk thistle) and its main constituent, silymarin, as a potential therapeutic plant in metabolic syndrome: a review. Phytother Res 2018;32:1933–49.10.1002/ptr.6153Search in Google Scholar PubMed

[5] Vahabzadeh M, Amirib N, Karimi G. Effects of silymarin on metabolic syndrome: a review. J Sci Food Agric 2018;98:4816–23.10.1002/jsfa.9115Search in Google Scholar PubMed

[6] Abenavoli L, Izzo AA, Milić N, Cicala C, Santini A, Capasso R. Milk thistle (Silybum marianum): a concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases. Phytother Res 2018;32:2202–13.10.1002/ptr.6171Search in Google Scholar PubMed

[7] Capasso F, Gaginella TS, Grandolini G, Izzo AA. Phytotherapy, a quick reference to herbal medicine. Springer Verlag, 2003. ISBN: 3540000526.10.1007/978-3-642-55528-2Search in Google Scholar

[8] Lino FG. Efeitos da silimarina e da silibina na patogênese da infecção aguda murina por Schistosoma mansoni. Dissertação de Mestrado apresentada ao Programa de Pós-Graduação em Ciências Farmacêuticas, Faculdade de Farmácia, da Universidade Federal do Rio de Janeiro, 2012.Search in Google Scholar

[9] Kim NC, Graf TN, Sparacino CM, Wani MC, Wall ME. Complete isolation and characterization of silybins and isosilybins from milk thistle (Silybum marianum). Org Biomol Chem 2003;1:1684–9.10.1002/chin.200338195Search in Google Scholar

[10] Polyak SJ, Oberlies NH, Pécheur EI, Dahari H, Ferenci P, Pawlotsky JM. Silymarin for HCV Infection. Antivir Ther 2013;18:141–7.10.3851/IMP2402Search in Google Scholar PubMed PubMed Central

[11] Mastron J, Siveen K, Sethi G, Bishayee A. Silymarin and hepatocellular carcinoma: a systematic, comprehensive, and critical review. Anti-Cancer Drugs 2015;26:475–86.10.1097/CAD.0000000000000211Search in Google Scholar PubMed

[12] Chambers CS, Holečkováa V, Petráskováa L, Biedermanna D, Valentováa K, Buchtab M, et al. The silymarin composition… and why does it matter??? Food Res Int 2017;100:339–53.10.1016/j.foodres.2017.07.017Search in Google Scholar PubMed

[13] Bijak M. Silybin, a Major Bioactive Component of Milk Thistle (Silybum marianum L. Gaernt.) Chemistry, Bioavailability, and Metabolism. Molecules 2017;22:1942.10.3390/molecules22111942Search in Google Scholar PubMed PubMed Central

[14] Voinovich D, Perissutti B, Grassi M, Passerini N, Bigotto A. Solid state mechanochemical activation of Silybum marianum dry extract with betacyclodextrins: Characterization and bioavailability of the coground systems. J Pharm Sci 2009;98:4119–29.10.1002/jps.21704Search in Google Scholar PubMed

[15] Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs 2001;61:2035–63.10.2165/00003495-200161140-00003Search in Google Scholar PubMed

[16] Schulz HU, Schürer M, Krumbiegel G, Wächter W, Weyhenmeyer R, Seidel G. The solubility and bioequivalence of silymarin preparations. Arzneimittelforschung 1995;45:61–4.Search in Google Scholar

[17] Rambaldi A, Jacobs BP, Laquinto G, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C liver diseases – a systematic Cochrane Hepato-Biliary group review with metaanalyses of randomized clinical trials. Am J Gastroenterol 2005;100:2583–91.10.1111/j.1572-0241.2005.00262.xSearch in Google Scholar PubMed

[18] Karimi G, Vahabzadeh M, Lari P, Rashedinia M, Moshiri M. “Silymarin”, a promising pharmacological agent for treatment of diseases. Iran J Basic Med Sci 2011;14:308–17.Search in Google Scholar

[19] Ni X, Wang H. Silymarin attenuated hepatic steatosis through regulation of lipid metabolism and oxidative stress in a mouse model of nonalcoholic fatty liver disease (NAFLD). Am J Transl Res 2016;8:1073–81.Search in Google Scholar

[20] Song Z, Deaciuc I, Song M, Lee DY, Liu Y, Ji X, et al. Silymarin protects against acute ethanolinduced hepatotoxicity in mice. Alcohol Clin Exp Res 2006;30:407–13.10.1111/j.1530-0277.2006.00063.xSearch in Google Scholar PubMed PubMed Central

[21] Wei F, Liu SK, Liu XY, Li ZJ, Li B, Zhou YL, et al. Meta-analysis: Silymarin and its combination therapy for the treatment of chronic hepatitis B. Eur J Clin Microbiol Infect Dis 2013;32:657–69.10.1007/s10096-012-1789-1Search in Google Scholar PubMed

[22] Wagoner J, Negash A, Kane OJ, Martinez LE, Nahmias Y, Bourne N, et al. Multiple effects of silymarin on the hepatitis C virus lifecycle. Hepatology 2010;51:1912–21.10.1002/hep.23587Search in Google Scholar PubMed PubMed Central

[23] Zaidi SNF, Mahboob T. Prevention of liver cirrhosis by Silymarin. Pak J Pharm Sci 2017;30:1203–11.Search in Google Scholar

[24] Freitag AF, Cardia GF, da Rocha BA, Aguiar RP, Silva-Comar FM, Spironello RA, et al. Hepatoprotective effect of silymarin (Silybum marianum) on hepatotoxicity induced by acetaminophen in spontaneously hypertensive rats. Evid-Based Complementary Altern Med 2015;538317. DOI: 10.1155/2015/538317.10.1155/2015/538317Search in Google Scholar PubMed PubMed Central

[25] Vargas-Mendoza N, Madrigal-Santillán E, Morales-González A, Esquivel-Soto J, Esquivel-Chirino C, García-Luna Y González-Rubio M, et al. Hepatoprotective effect of silymarin. World J Hepatol 2014;6:144–9.10.4254/wjh.v6.i3.144Search in Google Scholar PubMed PubMed Central

[26] Kim YC, Na JD, Kwon DY, Park JH. Silymarin prevents acetaminophen-induced hepatotoxicity via up-regulation of the glutathione conjugation capacity in mice. J Funct Foods 2018;49:235–40.10.1016/j.jff.2018.08.025Search in Google Scholar

[27] Papackova Z, Heczkova M, Dankova H, Sticova E, Lodererova A, Bartonova L, et al. Silymarin prevents acetaminophen-induced hepatotoxicity in mice. PLoS One 2018;13:e0191353.10.1371/journal.pone.0191353Search in Google Scholar PubMed PubMed Central

[28] Surai PF. Silymarin as a natural antioxidant: an overview of the current evidence and perspectives. Antioxidants (Basel) 2015;4:204–47.10.3390/antiox4010204Search in Google Scholar PubMed PubMed Central

[29] Serviddio G, Bellanti F, Stanca E, Lunetti P, Blonda M, Tamborra R, et al. Silybin exerts antioxidant effects and induces mitochondrial biogenesis in liver of rat with secondary biliary cirrhosis. Free Radic Biol Med 2014;73:117–26.10.1016/j.freeradbiomed.2014.05.002Search in Google Scholar PubMed

[30] Trakulsrichai S, Sriapha C, Tongpoo A, Udomsubpayakul U, Wongvisavakorn S, Srisuma S, et al. Clinical characteristics and outcome of toxicity from Amanita mushroom poisoning. Int J Gen Med 2017;10:395–400.10.2147/IJGM.S141111Search in Google Scholar PubMed PubMed Central

[31] Bousserouel S, Bour G, Kauntz H, Gossé F, Marescaux J, Raul F. Silibinin inhibits tumor growth in a murine orthotopic hepatocarcinoma model and activates the TRAIL apoptotic signaling pathway. Anticancer Res 2012;32:2455–62.Search in Google Scholar

[32] Yormaz S, Bulbuloglu E, Kurutas EB, Ciralik H, Yuzbasioglu MF, Yildiz H, et al. The comparison of the effects of hepatic regeneration after partial hepatectomy, Silybum marinaum, propofol, Nacetylcysteine and vitamin E on liver. Bratisl Lek Listy 2012;113:145–51.10.4149/BLL_2012_035Search in Google Scholar

[33] Seki E, Schwabe RF. Hepatic inflammation and fibrosis: functional links and key pathways. Hepatology 2015;61:1066–79.10.1002/hep.27332Search in Google Scholar PubMed PubMed Central

[34] Clichici S, Olteanu D, Filip A, Nagy AL, Oros A, Mircea PA. Beneficial effects of silymarin after the discontinuation of CCl4-induced liver fibrosis. J Med Food 2016;19:789–97.10.1089/jmf.2015.0104Search in Google Scholar PubMed

[35] Gharagozloo M, Jafari S, Esmaeil N, Javid EN, Bagherpour B, Rezaei A. Immunosuppressive effect of silymarin on mitogen-activated protein kinase signalling pathway: the impact on T cell proliferation and cytokine production. Basic Clin Pharmacol Toxicol 2013;113:209–14.10.1111/bcpt.12088Search in Google Scholar PubMed

[36] Esmaeil N, Anarakib SB, Gharagozloo M, Moayedi B. Silymarin impacts on immune system as an immunomodulator: One key for many locks. Int Immunopharmacology 2017;50:194–201.10.1016/j.intimp.2017.06.030Search in Google Scholar PubMed

[37] Hosseini A, Hosseinzadeh H. A review on the effects of Allium sativum (Garlic) in metabolic syndrome. J Endocrinol Invest 2015;38:1147–57.10.1007/s40618-015-0313-8Search in Google Scholar PubMed

[38] Zhan T, Digel M, Küch EM, Stremmel W, Füllekrug J. Silybin and dehydrosilybin decrease glucose uptake by inhibiting GLUT proteins. J Cell Biochem 2011;112:849–59.10.1002/jcb.22984Search in Google Scholar PubMed

[39] Bahem R, Hoffmann A, Azonpi A, Caballero-George C, Vanderheyden P. Modulation of calcium signaling of angiotensin AT1, endothelin ETA, and ETB receptors by silibinin, quercetin, crocin, diallyl sulfides, and ginsenoside Rb1. Planta Medica 2015;81:670–8.10.1055/s-0034-1383408Search in Google Scholar PubMed

[40] Derosa G, Romano D, D’Angelo A, Maffioli P. Berberis aristata/Silybum marianum fixed combination (Berberol^®) effects on lipid profile in dyslipidemic patients intolerant to statins at high dosages: a randomized, placebo-controlled, clinical trial. Phytomedicine 2015;22:231–7.10.1016/j.phymed.2014.11.018Search in Google Scholar PubMed

[41] Famouri F, Salehi M-M, Rostampour N, Hashemi E, Shahsanaee A. The effect of silymarin on non-alcoholic fatty liver disease children. J Herbmed Pharmacol 2017;6:16–20.Search in Google Scholar

[42] Poruba M, Kazdová L, Oliyarnyk O, Malinská H, Matusková Z, Tozzi di Angelo I, et al. Improvement bioavailability of silymarin ameliorates severe dyslipidemia associated with metabolic syndrome. Xenobiotica 2015;45:751–6.10.3109/00498254.2015.1010633Search in Google Scholar PubMed

[43] Sayin FK, Buyukbas S, Basarali MK, Alp H, Toy H, Ugurcu V. Effects of Silybum marianum extract on high-fat diet induced metabolic disorders in rats. Polish J Food Nutr Sci 2016;66:43–9.10.1515/pjfns-2015-0014Search in Google Scholar

[44] Guo Y, Wang S, Wang Y, Zhu T. Silymarin improved diet induced liver damage and insulin resistance by decreasing inflammation in mice. Pharm Biol 2016;54:2995–3000.10.1080/13880209.2016.1199042Search in Google Scholar PubMed

[45] Ni X, Wang H. Silymarin attenuated hepatic steatosis through regulation of lipid metabolism and oxidative stress in a mouse model of nonalcoholic fatty liver disease (NAFLD). Am J Transl Res 2016;8:1073–81.Search in Google Scholar

[46] Matsuda T, Ferreri K, Todorov I, Kuroda Y, Smith CV, Kandeel F, et al. Silymarin protects pancreatic β-cells against cytokine-mediated toxicity: implication of c-Jun NH2-terminal kinase and janus kinase/signal transducer and activator of transcription pathways. Endocrinology 2005;146:175–85.10.1210/en.2004-0850Search in Google Scholar PubMed

[47] Voroneanu L, Nistor I, Dumea R, Apetrii M, Covic A. Silymarin in type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. J Diabetes Res 2016;2016:5147468. DOI: 10.1155/2016/5147468.10.1155/2016/5147468.Search in Google Scholar

[48] Lu C, Huang C, Wang S, Chiu CH, Li LH, Hua KF, et al. Improvement of hyperglycemia in a murine model of insulin resistance and high glucose- and inflammasome-mediated IL-1β expressions in macrophages by silymarin. Chem Biol Interact 2018;290:12–8.10.1016/j.cbi.2018.05.004Search in Google Scholar PubMed

[49] Gu M, Zhao P, Huang J, Zhao Y, Wang Y, Li Y, et al. Silymarin ameliorates metabolic dysfunction associated with diet-induced obesity via activation of farnesyl X receptor. Front Pharmacol 2016;7:345.10.3389/fphar.2016.00345Search in Google Scholar PubMed PubMed Central

[50] Agarwal R, Agarwal C, Ichikawa HRP, Singh RP, Aggarwal BB. Anticancer potential of silymarin: from bench to bed side. Anticancer Res 2006;26:4457–98.Search in Google Scholar

[51] Razavi BM, Karimi G. Protective effect of silymarin against chemical-induced cardiotoxicity. Iran J Basic Med Sci 2016;19:916–23.Search in Google Scholar

[52] Vaughu C, Gotto AJ, Basson C. The evolving role of silymarin in management of atherosclerosis. J Am Coll Cardiol 2006;36:1–5.Search in Google Scholar

[53] Wu CH, Huang SM, Yen GC. Silymarin: a novel antioxidant with antiglycation and antiinflammatory properties in vitro and in vivo. Antioxid Redox Signal 2011;14:353–66.10.1089/ars.2010.3134Search in Google Scholar PubMed

[54] Alkuraishy HM, Alwindy S. Beneficial effects of silymarin on lipid profile in hyperlipidemic patients: placebo controlled clinical trail. Webmed Central Pharmacology 2012;3:WMC002966.Search in Google Scholar

[55] Hadi A, Pourmasoumi M, Mohammadi H, Symonds M, Miraghajani M. The effects of silymarin supplementation on metabolic status and oxidative stress in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of clinical trials. Complement Ther Med 2018;41:311–9.10.1016/j.ctim.2018.08.010Search in Google Scholar PubMed

[56] Stolf AM, Cardoso CC, Acco A. Effects of silymarin on diabetes mellitus complications: a review. Phytother Res 2017;31:366–74.10.1002/ptr.5768Search in Google Scholar PubMed

[57] Fallahzadeh MK, Dormanesh B, Sagheb MM, Roozbeh J, Vessal G, Pakfetrat M, et al. Effect of addition of silymarin to reninangiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial. Am J Kidney Dis 2012;60:896–903.10.1053/j.ajkd.2012.06.005Search in Google Scholar PubMed

[58] Koujan SE, Gargaria BP, Mobasseri M, Valizadeh H, Asghari-Jafarabadi M. Lower glycemic indices and lipid profile among type 2 diabetes mellitus patients who received novel dose of Silybum marianum (L.) Gaertn. (silymarin) extract supplement: a Triple-blinded randomized controlled clinical trial. Phytomedicine 2018;44:39–44.10.1016/j.phymed.2018.03.050Search in Google Scholar PubMed

[59] Tuorkey MJ, El-Desouki NL, Kamel RA. Cytoprotective effect of silymarin against diabetes-induced cardiomyocyte apoptosis in diabetic rats. Biomed Environ Sci 2015;28:36–43.Search in Google Scholar

[60] Amniattalab A, Malekinejad H, Rezabakhsh A, Rokhsartalab-Azar S, Alizade-Fanalou S. Silymarin: a novel natural agent to restore defective pancreatic beta cells in streptozotocin (STZ)-induced diabetic rats. Iran J Pharm Res 2016;15:493–500.Search in Google Scholar

[61] Stolf AM. Efeitos da silimarina sobre a angiogênese e estresse oxidativo em camundongos normoglicêmicos e diabéticos. Thesis of Pharmacology Doctorate Degree. UFPR. Curitiba, PR, Brazil, 2016.Search in Google Scholar

[62] El-Far YM, Zakaria MM, Gabr MM, El Gayar AM, El-Sherbiny IM, Eissa LA. A newly developed silymarin nanoformulation as a potential antidiabetic agent in experimental diabetes. Nanomedicine (Lond.) 2016;11:2581–602.10.2217/nnm-2016-0204Search in Google Scholar PubMed

[63] Rahimi R, Karimi J, Khodadadi I, Tayebinia H, Kheiripour N, Hashemnia M, et al. Silymarin ameliorates expression of urotensin II (U-II) and its receptor (UTR) and attenuates toxic oxidative stress in the heart of rats with type 2 diabetes. Biomed Pharmacother 2018;101:244–50.10.1016/j.biopha.2018.02.075Search in Google Scholar PubMed

[64] Heistad DD. Oxidative stress and vascular disease. Arterioscl Thromb Vasc Biol 2006;26:689–95.10.1161/01.ATV.0000203525.62147.28Search in Google Scholar PubMed

[65] Ahmad KA, Yuan Yuan D, Nawaz W, Ze H, Zhuo CX, Talal B, et al. Antioxidant therapy for management of oxidative stress induced hypertension. Free Radic Res 2017;51:428–38.10.1080/10715762.2017.1322205Search in Google Scholar PubMed

[66] Xu Y, Tappia PS, Neki NS, Dhalla NS. Prevention of diabetes-induced cardiovascular complications upon treatment with antioxidants. Heart Failure Rev 2014;19:113–21.10.1007/s10741-013-9379-6Search in Google Scholar PubMed

[67] Vasanthi R, ShriShriMal HN, Das DK. Phytochemicals from plants to combat cardiovascular disease. Curr Med Chem 2012;19:2242–51.10.2174/092986712800229078Search in Google Scholar PubMed

[68] Taleb A, Ahmad KA, Ihsan AU, Qu J, Lin N, Hezam K, et al. Antioxidant effects and mechanism of silymarin in oxidative stress induced cardiovascular diseases. Biomed Pharmacother 2018;102:689–98.10.1016/j.biopha.2018.03.140Search in Google Scholar PubMed

[69] Herrero M, Cifuentes A, Ibañez E. Sub-and supercritical fluid extraction of functional ingredients from different natural sources: Plants, food-by-products, algae and microalgae: a review. Food Chem 2006;98:136–48.10.1016/j.foodchem.2005.05.058Search in Google Scholar

[70] Mohd Fozi NF, Mazlan M, Shuid AN, Isa Naina M. Milk thistle: a future potential anti-osteoporotic and fracture healing agent. Curr Drug Targets 2013;14:1659–66.10.2174/13894501113146660222Search in Google Scholar PubMed

[71] Turgut F, Bayrak O, Catal F, Bayrak R, Atmaca AF, Koc A, et al. Antioxidant and protective effects of silymarin on ischemia and reperfusion injury in the kidney tissues of rats. Int Urol Nephrol 2008;40:453–60.10.1007/s11255-008-9365-4Search in Google Scholar PubMed

[72] Sissung TM, Baum CE, Kirkland CT, Gao R, Gardner ER, Figg WD. Pharmacogenetics of membrane transporters: an update on current approaches. Mol Biotechnol 2010;44:152–67.10.1007/s12033-009-9220-6Search in Google Scholar PubMed PubMed Central

[73] Di Meo F, Lemaur V, Cornil J, Lazzaroni R, Duroux JL, Olivier Y, et al. Free radical scavenging by natural polyphenols: atom versus electron transfer. J Phys Chem A 2013;117:2082–92.10.1021/jp3116319Search in Google Scholar PubMed

[74] Surh Y. NF-κB and Nrf2 as potential chemopreventive targets of some anti-inflammatory and antioxidative phytonutrients with anti-inflammatory and antioxidative activities. Asia Pac J Clin Nutr 2008;17:269–72.Search in Google Scholar

[75] Kim EJ, Lee MY, Jeon YJ. Silymarin inhibits morphological changes in LPSstimulated macrophages by blocking NF-kappaB pathway. Korean J Physiol Pharmacol 2015;19:211–8.10.4196/kjpp.2015.19.3.211Search in Google Scholar PubMed PubMed Central

[76] Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007;117:1175–83.10.1172/JCI31537Search in Google Scholar PubMed PubMed Central

[77] Wang MJ, Lin WW, Chen HL, Chang YH, Ou HC, Kuo JS, et al. Silymarin protects dopaminergic neurons against lipopolysaccharide-induced neurotoxicity by inhibiting microglia activation. Eur J Neurosci 2002;16:2103–12.10.1046/j.1460-9568.2002.02290.xSearch in Google Scholar PubMed

[78] Hou YC, Liou KT, Chern CM, Wang YH, Liao JF, Chang S, et al. Preventive effect of silymarin in cerebral ischemia-reperfusion-induced brain injury in rats possibly through impairing NF-kappaB and STAT-1 activation. Phytomedicine 2010;17:963–73.10.1016/j.phymed.2010.03.012Search in Google Scholar

[79] Kittur S, Wilasrusmee S, Pedersen WA, Mattson MP, Straube-West K, Wilasrusmee C, et al. Neurotrophic and neuroprotective effects of milk thistle (Silybum marianum) on neurons in culture. J Mol Neurosci 2002;18:265–69.10.1385/JMN:18:3:265Search in Google Scholar

[80] Chtourou Y, Fetoui H, Sefi M, Trabelsi K, Barkallah M, Boudawara T, et al. Silymarin, a natural antioxidant, protects cerebral cortex against manganese-induced neurotoxicity in adult rats. Biometals 2010;23:985–96.10.1007/s10534-010-9345-xSearch in Google Scholar PubMed

[81] Pandima DK, Malar DS, Braidy N, Nabavi SM, Nabavi SF. A mini review on the chemistry and neuroprotective effects of silymarin. Curr Drug Targets 2017;18:1529–36.10.2174/1389450117666161227125121Search in Google Scholar

[82] El-Marasy SA, Abd-Elsalam RM, Ahmed-farid OA. Ameliorative effect of Silymarin on Scopolamine-induced Dementia in rats. Open Access Maced J Med Sci 2018;6:1215–24.10.3889/oamjms.2018.257Search in Google Scholar PubMed PubMed Central

[83] Ullah H, Khan H. Anti-parkinson potential of silymarin: mechanistic insight and therapeutic standing. Front Pharmacol 2018;9:422.10.3389/fphar.2018.00422Search in Google Scholar PubMed PubMed Central

[84] Li L, Sun H, Liu W, Zhao HY, Shao ML. Silymarin protects against acrylamide-induced neurotoxicity via Nrf2 signalling in PC12 cells. Food Chem Toxicol 2017;102:93–101.10.1016/j.fct.2017.01.021Search in Google Scholar PubMed

[85] Muley MM, Thakare VN, Patil RR, Kshirsagar AD, Naik SR. Silymarin improves the behavioural biochemical and histoarchitecture alterations in focal ischemic rats: Comparative evaluation with piracetam and protocatachuic acid. Pharmacol Biochem Behav 2012;102:286–93.10.1016/j.pbb.2012.05.004Search in Google Scholar PubMed

[86] Khoshnoodi M, Fakhraei N, Dehpour AR. Possible involvement of nitric oxide in antidepressant-like effect of silymarin in male mice. Pharm Biol 2015;28:1–7.10.3109/13880209.2014.942787Search in Google Scholar PubMed

[87] Thakare VN, Aswar MK, Kylkarni YP. Silymarin ameliorates experimentally induced depressive like behavior in rats: involvement of hippocampal BDNF signaling, inflammatory cytokines and oxidative stress response. Physiol Beahv 2017;179:401–10.10.1016/j.physbeh.2017.07.010Search in Google Scholar PubMed

[88] Thakare VN, Patil RR, Oswal RJ, Dhakane VD, Aswar MK, Patel BM. Therapeutic potential of silymarin in chronic unpredictable mild stress induced depressive-like behavior in mice. J Psychopharmacol 2018;32:223–35.10.1177/0269881117742666Search in Google Scholar PubMed

[89] Deep G, Agarwal R. Chemopreventive efficacy of silymarin in skin and prostate cancer. Integr Cancer Ther 2007;6:130–45.10.1177/1534735407301441Search in Google Scholar PubMed

[90] Tyagi A, Raina K, Singh RP, Gu M, Agarwal C, Harrison G, et al. Chemopreventive effects of silymarin and silibinin on N-butyl-N-(4-hydroxybutyl) nitrosamine induced urinary bladder carcinogenesis in male ICR mice. Mol Cancer Ther 2007;6:3248–55.10.1158/1535-7163.MCT-07-2006Search in Google Scholar PubMed

[91] Ramasamy K, Agarwal R. Multitargeted therapy of cancer by silymarin. Cancer Lett 2008;269:352–62.10.1016/j.canlet.2008.03.053Search in Google Scholar PubMed PubMed Central

[92] Féher J, Lengye G. Silymarin in the prevention and treatment of liver diseases and primary liver cancer. Curr Pharm Biotechnol 2012;13:210–7.10.2174/138920112798868818Search in Google Scholar PubMed

[93] Khorsandi L, Saki G, Bavarsad N, Mombeini M. Silymarin induces a multi-targeted cell death process in the human colon cancer cell line HT-29. Biomed Pharmacother 2017;94:890–7.10.1016/j.biopha.2017.08.015Search in Google Scholar PubMed

[94] Won DH, Kim LH, Jang B, Yang IH, Kwon HJ, Jin B, et al. In vitro and in vivo anti-cancer activity of silymarin on oral cancer. Tumor Biology 2018;40:1–11.10.1177/1010428318776170Search in Google Scholar PubMed

[95] Agarwal C, Tyagi A, Kaur M, Agarwal R. Silibinin inhibits constitutive activation of Stat3, and causes caspase activation and apoptotic death of human prostate carcinoma DU145 cells. Carcinogenesis 2007;28:1463–70.10.1093/carcin/bgm042Search in Google Scholar PubMed

[96] Feng B, Meng R, Huang B, Shen S, Bi Y, Zhu D. Silymarin alleviates hepatic oxidative stress and protects against metabolic disorders in high-fat diet-fed mice. Free Radic Res 2016;50:314–27.10.3109/10715762.2015.1116689Search in Google Scholar PubMed

[97] Adhikari M, Dhaker A, Adhikari J, Ivanov V, Singh V, Chawla R, et al. In vitro studies on radioprotective efficacy of silymarin against γ-irradiation. Int J Radiat Biol 2013;89:200–11.10.3109/09553002.2013.741285Search in Google Scholar PubMed

[98] Oufi HG, Al-Shawi NN. The effects of different doses of silibinin in combination with methotrexate on testicular tissue of mice. Eur J Pharmacol 2014;730:36–40.10.1016/j.ejphar.2014.02.010Search in Google Scholar PubMed

[99] Adhikari M, Arora R. Nano-silymarin provides protection against γ-radiation-induced oxidative stress in cultured human embryonic kidney cells. Mutat Res Genet Toxicol Environ Mutagen 2015;792:1–11.10.1016/j.mrgentox.2015.08.006Search in Google Scholar PubMed

[100] Fatehi D, Mohammadi M, Shekarchi B, Shabani A, Seify M, Rostamzadeh A. Radioprotective effects of Silymarin on the sperm parameters of NMRI mice irradiated with γ-rays. J Photochem Photobiol B 2018;178:489–95.10.1016/j.jphotobiol.2017.12.004Search in Google Scholar PubMed

[101] Jabini R, Jaafari MR, Vahdati Hasani F, Ghazizadeh F, Khamesipour A, Karimi G. Effects of combined therapy with silymarin and glucantime on leishmaniasis induced by Leishmania major in BALB/c mice. Drug Res (Stuttg) 2015;65:119–24.10.1055/s-0034-1370914Search in Google Scholar PubMed

[102] Shokri A, Akhtari J, Keighobadi M, Fakhar M, Teshnizi SH, Emami S, et al. Promising antileishmanial effectiveness of doxorubicin and doxil against Leishmania major: an in vitro assay. Asian Pac J Trop Med 2017;10:544–8.10.1016/j.apjtm.2016.09.014Search in Google Scholar PubMed

[103] Faridnia R, Kalani H, Fakhar M, Akhtari J. Investigating in vitro anti-leishmanial effects of silibinin and silymarin on Leishmania major. Ann Parasitol 2018;64:29–35.Search in Google Scholar

[104] Mata-Santos HA, Lino FG, Rocha CC, Paiva CN, Castelo Branco MT, Pyrrho Ados S. Silymarin treatment reduces granuloma and hepatic fibrosis in experimental schistosomiasis. Parasitol Res 2010;107:1429–34.10.1007/s00436-010-2014-8Search in Google Scholar PubMed

[105] El-Sayed NM, Fathy GM, Abdel-Rahman S, El-Shafei MA. Cytokine patterns in experimental schistosomiasis mansoni infected mice treated with silymarin. J Parasit Dis 2016;40:922–9.10.1007/s12639-014-0606-4Search in Google Scholar PubMed PubMed Central

[106] Lani R, Hassandarvish P, Chiam CW, Moghaddam E, Chu JJ, Rausalu K, et al. Antiviral activity of silymarin against chikungunya virus. Sci Rep 2015;5:11421.10.1038/srep11421Search in Google Scholar PubMed PubMed Central

[107] Liu CH, Lin CC, Hsu WC, Chung CY, Lin CC, Jassey A, et al. Highly bioavailable silibinin nanoparticles inhibit HCV infection. Gut 2017;66:1853–61.10.1136/gutjnl-2016-312019Search in Google Scholar PubMed

[108] Huang J, Liu S, Li Z, Cao L, Ouyang L. Effect of lamivudine and silymarin on liver fibrosis-relevant factors in HBV transgenic mice with alcohol drinking. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2017;28:257–63.Search in Google Scholar

[109] Camini FC, Silva TF, Caetano CCS, Almeida LT, Ferraz AC, Alves Vitoreti VM, et al. Antiviral activity of silymarin against Mayaro virus and protective effect in virus-induced oxidative stress. Antiviral Res 2018;158:8–12.10.1016/j.antiviral.2018.07.023Search in Google Scholar PubMed

[110] Gharagozloo M, Khoshdel Z, Amirghofran Z. The effect of an iron (III) chelator, silybin, on the proliferation and cell cycle of Jurkat cells: a comparison with desferrioxamine. Eur J Pharmacol 2008;589:1–7.10.1016/j.ejphar.2008.03.059Search in Google Scholar PubMed

[111] Hutchinson C, Bomford A, Geissler CA. The iron-chelating potential of silybin in patients with hereditary haemochromatosis. Eur J Clin Nutr 2010;64:1239–41.10.1038/ejcn.2010.136Search in Google Scholar PubMed PubMed Central

[112] Gharagozloo M, Moayedi B, Zakerinia M, Hamidi M, Karimi M, Maracy M, et al. Combined therapy of silymarin and desferrioxamine in patients with β-thalassemia major: a randomized double-blind clinical trial. Fundam Clin Pharmacol 2009;23:359–65.10.1111/j.1472-8206.2009.00681.xSearch in Google Scholar PubMed

[113] Moayedi B, Gharagozloo M, Esmaeil N, Maracy MR, Hoorfar H, Jalaeikar M. A randomized double-blind, placebo-controlled study of therapeutic effects of silymarin in β-thalassemia major patients receiving desferrioxamine. Eur J Haematol 2013;90:202–9.10.1111/ejh.12061Search in Google Scholar PubMed

[114] Hagag A. Therapeutic value of combined therapy with deferiprone and silymarin as iron chelators in Egyptian children with beta thalassemia major. Infect Disord Drug Targets 2015;15:189–95.10.2174/1871526515666150731113305Search in Google Scholar PubMed

[115] Darvishi-Khezri H, Salehifar E, Kosaryan M. The impact of silymarin on antioxidant and oxidative status in patients with β-thalassemia major: A crossover, randomized controlled trial. Complement Ther Med 2017;35:25–32.10.1016/j.ctim.2017.08.007Search in Google Scholar PubMed

[116] Darvishi-Khezri H, Salehifar E, Kosaryan M, Karami H, Mahdavi M, Alipour A, et al. Iron-chelating effect of silymarin in patients with β-thalassemia major: a crossover randomised control trial. Phytother Res 2018;32:496–503.10.1002/ptr.5995Search in Google Scholar PubMed

[117] Netto G, Jose J. Development, characterization, and evaluation of sunscreen cream containing solid lipid nanoparticles of silymarin. J Cosmet Dermatol 2017;17:1–11.10.1111/jocd.12470Search in Google Scholar

[118] Altaei T. The treatment of melasma by silymarin cream. BMC Dermatol 2012;12:18.10.1186/1471-5945-12-18Search in Google Scholar PubMed PubMed Central

[119] Rajnochová Svobodová A, Gabrielová E, Michaelides L, Kosina P, Ryšavá A, Ulrichová J, et al. UVA-photoprotective potential of silymarin and silybin. Arch Dermatol Res 2018;310:413–24.10.1007/s00403-018-1828-6Search in Google Scholar PubMed